Education
About Us
Working with TipRanks
Follow Us
Purple Biotech Ltd. (IL:PPBT)
:PPBT
PPBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range3.90 - 21.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)684.40K
Market Cap
23.85M
Enterprise ValueN/A
Total Cash (Recent Filing)8.52M
Total Debt (Recent Filing)$183.00K
Price to Earnings (P/E)―
Beta-0.56
Next Earnings
Aug 14, 2025EPS EstimateN/A
Last Dividend Ex-Date
Oct 30, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding567,781,000
10 Day Avg. Volume804,564
30 Day Avg. Volume684,397
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Purple Biotech News
PPBT FAQ
What was Purple Biotech Ltd.’s price range in the past 12 months?
Purple Biotech Ltd. lowest stock price was 3.90 and its highest was 21.00 in the past 12 months.
What is Purple Biotech Ltd.’s market cap?
Purple Biotech Ltd.’s market cap is 23.85M.
When is Purple Biotech Ltd.’s upcoming earnings report date?
Purple Biotech Ltd.’s upcoming earnings report date is Aug 14, 2025 which is in 39 days.
How were Purple Biotech Ltd.’s earnings last quarter?
Purple Biotech Ltd. released its earnings results on May 21, 2025. The company reported -0.3 earnings per share for the quarter, missing the consensus estimate of N/A by -0.3.
Is Purple Biotech Ltd. overvalued?
According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued.
Does Purple Biotech Ltd. pay dividends?
Purple Biotech Ltd. pays a Notavailable dividend of 249.549 which represents an annual dividend yield of N/A. See more information on Purple Biotech Ltd. dividends here
What is Purple Biotech Ltd.’s EPS estimate?
Purple Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech Ltd. have?
Purple Biotech Ltd. has 567,781,000 shares outstanding.
What happened to Purple Biotech Ltd.’s price movement after its last earnings report?
Purple Biotech Ltd. reported an EPS of -0.3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.878%.
Which hedge fund is a major shareholder of Purple Biotech Ltd.?
Currently, no hedge funds are holding shares in IL:PPBT
Company Description
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.